Mar 08, 2023 8:00am EST Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Mar 03, 2023 8:00am EST Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Mar 02, 2023 8:00am EST Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
Feb 07, 2023 8:00am EST Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Feb 02, 2023 8:00am EST Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
Jan 09, 2023 8:00am EST Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Dec 21, 2022 8:00am EST Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
Nov 14, 2022 4:05pm EST Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update